Showing results (141-150 of 376) with videos related to

Sort By:
Pageof 38
AIDS (London, England)|November 25, 2011
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran, Esteban Martinez, Maria Saumoy, et al.
The Journal of Antimicrobial Chemotherapy|May 9, 2012
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteersJavier A Estévez, José Moltó, Laura Tuneu, et al.
AIDS (London, England)|April 23, 2008
The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromesMaria Saumoy, Miguel López-Dupla, Sergi Veloso, et al.
AIDS (London, England)|January 16, 2008
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adultsJosep Mallolas, Judith Pich, María Peñaranda, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2016
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patientsAdrian Curran, Jhon Rojas, Alfonso Cabello, et al.
AIDS Research and Human Retroviruses|December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer, Luis del Rio, Esteban Martínez, et al.
The Journal of Antimicrobial Chemotherapy|December 20, 2014
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trialJosé Moltó, Marta Valle, Elena Ferrer, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19Leticia Alserawan, Patricia Peñacoba, Sandra Elizabet Orozco Echevarría, et al.
Clinical Pharmacokinetics|January 5, 2007
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosisJosé Moltó, Marta Valle, Asunción Blanco, et al.
Pageof 38